|
Name |
Chaetoglobosin U
|
Molecular Formula | C32H36N2O5 | |
IUPAC Name* |
(1R,4R,8R,9S,11E,13R,14S,16R,17S,18R,19S)-6-hydroxy-19-(1H-indol-3-ylmethyl)-7,9,16,17-tetramethyl-15-oxa-20-azapentacyclo[11.8.0.01,18.04,8.014,16]henicosa-6,11-diene-2,5,21-trione
|
|
SMILES |
C[C@H]1C/C=C/[C@H]2[C@H]3[C@](O3)([C@H]([C@@H]4[C@@]2(C(=O)C[C@@H]5[C@@H]1C(=C(C5=O)O)C)C(=O)N[C@H]4CC6=CNC7=CC=CC=C76)C)C
|
|
InChI |
InChI=1S/C32H36N2O5/c1-15-8-7-10-21-29-31(4,39-29)17(3)26-23(12-18-14-33-22-11-6-5-9-19(18)22)34-30(38)32(21,26)24(35)13-20-25(15)16(2)27(36)28(20)37/h5-7,9-11,14-15,17,20-21,23,25-26,29,33,36H,8,12-13H2,1-4H3,(H,34,38)/b10-7+/t15-,17-,20+,21-,23-,25-,26-,29-,31+,32+/m0/s1
|
|
InChIKey |
MRENMDHAGXAXRK-QFHPAQOTSA-N
|
|
Synonyms |
Chaetoglobosin U; CHEBI:68733; CHEMBL448756; Q27137152; (1R,4R,8R,9S,11E,13R,14S,16R,17S,18R,19S)-6-hydroxy-19-(1H-indol-3-ylmethyl)-7,9,16,17-tetramethyl-15-oxa-20-azapentacyclo[11.8.0.01,18.04,8.014,16]henicosa-6,11-diene-2,5,21-trione; (3aR,5aR,8S,8aR,9S,9aR,10aS,10bR,11E,14S,14aR)-2-hydroxy-8-(1H-indol-3-ylmethyl)-1,9,9a,14-tetramethyl-3a,4,7,8,8a,9,9a,10a,10b,13,14,14a-dodecahydro-3H-cyclopenta[7,8]cyclodeca[1,2-d]oxireno[f]isoindole-3,5,6-trione
|
|
CAS | 882516-41-8 | |
PubChem CID | 11570022 | |
ChEMBL ID | CHEMBL448756 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 528.6 | ALogp: | 3.6 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 112.0 | Aromatic Rings: | 7 |
Heavy Atoms: | 39 | QED Weighted: | 0.29 |
Caco-2 Permeability: | -4.847 | MDCK Permeability: | 0.00001450 |
Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.084 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.033 |
30% Bioavailability (F30%): | 0.221 |
Blood-Brain-Barrier Penetration (BBB): | 0.422 | Plasma Protein Binding (PPB): | 97.42% |
Volume Distribution (VD): | 0.346 | Fu: | 3.35% |
CYP1A2-inhibitor: | 0.055 | CYP1A2-substrate: | 0.716 |
CYP2C19-inhibitor: | 0.597 | CYP2C19-substrate: | 0.754 |
CYP2C9-inhibitor: | 0.393 | CYP2C9-substrate: | 0.073 |
CYP2D6-inhibitor: | 0.483 | CYP2D6-substrate: | 0.21 |
CYP3A4-inhibitor: | 0.946 | CYP3A4-substrate: | 0.473 |
Clearance (CL): | 7.55 | Half-life (T1/2): | 0.254 |
hERG Blockers: | 0.184 | Human Hepatotoxicity (H-HT): | 0.263 |
Drug-inuced Liver Injury (DILI): | 0.242 | AMES Toxicity: | 0.021 |
Rat Oral Acute Toxicity: | 0.868 | Maximum Recommended Daily Dose: | 0.937 |
Skin Sensitization: | 0.281 | Carcinogencity: | 0.179 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.966 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002678 | 0.779 | D0V3ZA | 0.268 | ||||
ENC004469 | 0.722 | D0W7WC | 0.264 | ||||
ENC004470 | 0.717 | D01TSI | 0.261 | ||||
ENC003586 | 0.703 | D09NNH | 0.261 | ||||
ENC004465 | 0.690 | D0SP3D | 0.260 | ||||
ENC004473 | 0.664 | D02DMQ | 0.238 | ||||
ENC002646 | 0.632 | D05EJG | 0.238 | ||||
ENC004447 | 0.561 | D05MQK | 0.237 | ||||
ENC002120 | 0.553 | D09ZIO | 0.229 | ||||
ENC002681 | 0.550 | D00YLW | 0.226 |